The document summarizes the various classes of noninsulin medications available for treating type 2 diabetes. It describes the mechanism of action, dosing, potential adverse effects, and notes for each class, which includes sulfonylureas, meglinitides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. The increasing number of treatment options available makes developing universal treatment plans difficult due to each drug's unique properties and potential side effects. A patient-centered approach that considers individual factors is emphasized for effective management of the disease.